To include your compound in the COVID-19 Resource Center, submit it here.

Sanofi, Regeneron report Phase III data for Dupixent in atopic dermatitis

In September, Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data from the Phase III CAFÉ trial in 325 patients with moderate to severe atopic dermatitis showing that 300 mg Dupixent dupilumab (REGN668, SAR231893) weekly and

Read the full 372 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE